Immix Biopharma (IMMX) Equity Average (2021 - 2026)

Immix Biopharma has disclosed Equity Average across 6 years of filings, most recently posting $89.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $89.1 million, up 679.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.1 million (up 679.87% YoY), and the FY2025 annual result was $53.5 million, up 263.43% from the prior year.
• Equity Average came in at $89.1 million for Q1 2026 at Immix Biopharma, up from $51.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $89.1 million in Q1 2026 to a low of $6.5 million in Q3 2025.
• The 5-year median for Equity Average is $17.4 million (2022), against an average of $22.2 million.
• Across the five-year window, Equity Average sank 72.35% in 2025 and surged 679.87% in 2026, its largest moves.
• Immix Biopharma's Equity Average stood at $15.0 million in 2022, then advanced by 19.87% to $17.9 million in 2023, then retreated by 14.09% to $15.4 million in 2024, then soared by 231.35% to $51.0 million in 2025, then jumped by 74.56% to $89.1 million in 2026.
• The last three Equity Average figures came in at $89.1 million (Q1 2026), $51.0 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.